The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
62
Randomized participants will receive either 150 mg oral sulindac twice daily.
placebo pills twice daily
Cedars Sinai - Cancer
Los Angeles, California, United States
Stony Brook University Cancer Center
Stony Brook, New York, United States
Change in percent breast density by MRI between treatment arms
Time frame: 12 months
Change in percent breast density by MRI between treatment arms
Time frame: 6 months
Changes in in percent breast density by MRI within and between treatment arms, stratified by use of aromatase inhibitors
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.